Kolexia
Le Gouill Steven Hématologie
Le Gouill Steven
Hématologie
Clcc Institut Curie
Paris, France
594 Activités
1.5 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Lymphome à cellules du manteau Lymphome B Lymphome B diffus à grandes cellules Lymphome malin non hodgkinien Lymphome folliculaire Maladie de Hodgkin Myélome multiple Tumeurs hématologiques

Collaborateurs

Voir plus
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Gastinne Thomas
Gastinne Thomas
Hôpital Hôtel-Dieu Nantes, Nantes, France
Morschhauser Franck
Morschhauser Franck
Centre Hospitalier de Lille, Lille, France
Cartron Guillaume
Cartron Guillaume
Hôpital Saint-Éloi, Montpellier, France

Industries

Voir plus
Celgene
304 collaboration(s)
Dernière en 2021
Janssen
24 collaboration(s)
Dernière en 2022
Novartis
9 collaboration(s)
Dernière en 2021
Roche
8 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
BELINDA: Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Essai Clinique (Novartis)   20 mars 2024
RELEVANCE: A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The "RELEVANCE" Trial (Rituximab Lenalidomide Versus ANy ChEmotherapy)is Being Conducted as Two Companion Studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the Combined Total of 1000 Patients Enrolled in Both Studies Will be Analyzed.
Essai Clinique (Celgene)   13 mars 2024
LyMa101: Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma
Essai Clinique (Janssen)   27 février 2024
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma: An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma
Essai Clinique (Acerta Pharma BV)   19 janvier 2024
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma
Essai Clinique (Institut Curie)   10 janvier 2024
REVCCI: Use of Virtual Reality Mask or Music Therapy for Analgesia and Anxiolytic Purpose When Totally Implanted Venous Access Device (IVAD) for Chemotherapy Under Local Anesthesia
Essai Clinique (Institut Curie)   10 janvier 2024
ECLECTIC: EstroTEP and Circulating Biomarkers to Determine the Optimal Second Line Therapy for ER-positive HER2-negative Metastatic Breast Cancer Patients
Essai Clinique (Zionexa)   08 janvier 2024
Impact of the practice of touch-massage® by a nurse on the anxiety of patients with hematological disorders hospitalized in a sterile environment, a randomized, controlled study.
BMC complementary medicine and therapies   02 janvier 2024
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   18 décembre 2023